Peptides for Muscle Growth: What the Evidence Actually Shows

The category also mixes together very different substances. Sermorelin, ipamorelin, and CJC-1295 stimulate growth hormone signaling. MK-677 is an oral, non-peptide growth hormone secretagogue. BPC-157 and TB-500 are promoted for injury repair, not direct muscle growth. IGF-1 is a prescription growth factor with legitimate medical uses. Follistatin is an experimental regulator of the myostatin pathway.

Most are unapproved for muscle building. Many are prohibited in tested sports. Products sold online may not be equivalent to anything used in clinical research.

Here is what the evidence actually shows.

Do peptides actually build muscle?

Some compounds can increase growth hormone, IGF-1, or measured lean mass, but there is little evidence that the commonly marketed muscle peptides improve strength or athletic performance in healthy adults.

That distinction matters because lean body mass is not a synonym for functional muscle.

A body composition scan can count water, connective tissue, organs, and other fat-free tissue as lean mass. Growth hormone pathway drugs can cause fluid retention, which may increase a lean-mass measurement without producing an equivalent increase in contractile muscle or strength.

Research with actual recombinant human growth hormone illustrates the problem. In one controlled study of older men, growth hormone increased lean body mass, but it did not add to the strength gains produced by resistance training.

A similar pattern appears in several studies of growth hormone secretagogues and IGF-1. Laboratory markers rise. Lean mass may rise modestly. Functional outcomes often remain unchanged or uncertain.

Which peptides are used for muscle growth?

The compounds most often associated with muscle growth fall into four groups: growth hormone releasing agents, repair peptides, growth factors, and myostatin-related compounds.

Growth hormone releasing agents

These compounds stimulate the body's growth hormone axis rather than supplying growth hormone directly.

Sermorelin is a synthetic fragment of growth hormone-releasing hormone, commonly shortened to GHRH. It stimulates the pituitary gland to release growth hormone.

Ipamorelin is a growth hormone secretagogue that activates the ghrelin receptor. Small human pharmacology studies show that it can cause a short pulse of growth hormone release.

CJC-1295 is a longer-acting GHRH analogue. Early human trials found that it raised growth hormone and IGF-1 for several days. Those trials were designed mainly to study pharmacology and short-term safety, not muscle growth or athletic performance.

MK-677, also called ibutamoren, is not a peptide. It is an orally active ghrelin receptor agonist and growth hormone secretagogue. It is often grouped with peptides because it increases growth hormone and IGF-1 through a related pathway.

Repair peptides

BPC-157 is a synthetic 15-amino-acid compound promoted for tendon, ligament, muscle, and gastrointestinal repair. We cover it in depth in our BPC-157 evidence guide.

TB-500 is generally used to refer to a synthetic fragment associated with thymosin beta-4. Full-length thymosin beta-4 is a naturally occurring protein involved in actin regulation, cell movement, blood vessel formation, and tissue repair. The short fragment marketed as TB-500 is not automatically interchangeable with full-length thymosin beta-4. See our TB-500 evidence guide for the full picture.

Growth factors

IGF-1, or insulin-like growth factor 1, is a naturally occurring hormone downstream of growth hormone. A recombinant prescription version, mecasermin, is FDA approved for a narrow pediatric indication involving severe primary IGF-1 deficiency.

Products marketed as IGF-1 LR3, IGF-1 DES, and mechano growth factor are modified or purported variants marketed for muscle growth. They do not have FDA approval for bodybuilding or performance enhancement.

Follistatin and myostatin inhibition

Follistatin is a naturally occurring protein that binds activins and can inhibit signaling involving myostatin, a regulator that limits muscle growth.

The internet frequently refers to follistatin-344 as though it were an established muscle-building medication. It is not. Most dramatic muscle-growth findings come from animal experiments or experimental gene-transfer research, not clinical use of a retail peptide product.

What does the human evidence really show?

The human evidence ranges from modest clinical findings in selected patient groups to almost no reliable evidence for the versions sold for bodybuilding.

Sermorelin

Sermorelin can stimulate growth hormone release in humans. It was previously marketed in the United States for evaluating or treating certain forms of growth hormone deficiency in children, but that commercial product was discontinued.

Research in older adults has examined GHRH analogues as a way to restore age-related growth hormone signaling. Some studies reported changes in growth hormone, IGF-1, body composition, or selected metabolic measures. The evidence does not establish sermorelin as a muscle-building treatment for healthy adults.

This is a recurring theme. A compound can have a real biological effect without having proven bodybuilding benefits.

Ipamorelin

Ipamorelin has human pharmacology data showing that it stimulates growth hormone release. One study characterized its concentration and growth hormone response after administration to healthy volunteers.

That is not evidence that it increases muscle size, strength, recovery, or performance over time.

Much of the frequently cited body-composition evidence for ipamorelin comes from animal research. One early experiment examining growth and body weight was performed in rats, not people.

There are no robust, published randomized trials demonstrating that ipamorelin produces meaningful muscle or strength gains in healthy lifters.

CJC-1295

CJC-1295 has more direct human pharmacology evidence than many research peptides.

In randomized, placebo-controlled early-phase trials, CJC-1295 produced prolonged increases in growth hormone and IGF-1. In a separate analysis, basal growth hormone levels rose substantially, while mean growth hormone and IGF-1 also increased.

The studies did not establish improved muscle strength, hypertrophy, athletic performance, or injury recovery. They showed that the molecule affects its intended hormone pathway.

That gap is important. Higher IGF-1 does not guarantee larger or stronger muscles, and it does not establish that the overall risk-benefit balance is favorable.

MK-677, or ibutamoren

MK-677 has the most meaningful human body-composition evidence in this group, but the findings are much less impressive than online marketing often suggests.

In a randomized study of healthy older adults, MK-677 increased growth hormone and IGF-1 and increased fat-free mass over 12 months. It did not produce significant improvements in strength or physical function. The study was not designed to show bodybuilding benefits in young, resistance-trained adults.

Shorter studies in men with obesity also found increased growth hormone and IGF-1. One trial reported impaired glucose handling during an oral glucose tolerance test.

A larger trial in people with Alzheimer's disease found that MK-677 increased IGF-1 but did not slow clinical progression.

The honest conclusion is that MK-677 can alter the growth hormone axis and may increase fat-free mass in some populations. It has not been shown to produce reliable strength or performance benefits in healthy athletes.

BPC-157

The muscle and tendon claims surrounding BPC-157 are based mainly on animal studies.

Rodent experiments have reported effects on tendon, ligament, muscle, nerve, and gastrointestinal injury models. For example, a rat study reported improved healing after surgically created medial collateral ligament injury.

Human evidence remains extremely limited.

A small retrospective report described knee-pain outcomes after injections involving BPC-157, alone or combined with another peptide. It included only 16 patients, had no placebo group, used subjective outcomes, and did not establish muscle growth or accelerated athletic recovery.

A 2025 pilot safety report involved intravenous BPC-157 in only two healthy adults. It was not an efficacy trial and cannot establish general safety.

Recent clinical reviews continue to describe the musculoskeletal evidence for BPC-157 as largely preclinical and unvalidated in controlled human trials.

BPC-157 has not been shown to build muscle in humans.

TB-500 and thymosin beta-4

Thymosin beta-4 has biologically plausible roles in tissue repair, cell migration, blood vessel formation, and wound healing. Laboratory and animal studies have produced encouraging findings in several tissues.

That evidence does not validate TB-500 for muscle recovery.

The FDA review in 2026 stated that it had not identified published human clinical studies or human safety studies of the TB-500 fragment.

This distinction is often lost online. Research involving full-length thymosin beta-4, cells, animals, wounds, the heart, or the eye cannot simply be applied to a short fragment sold as an athletic recovery drug.

There is no reliable human evidence that TB-500 builds muscle, prevents training injuries, or speeds return to sport.

IGF-1

IGF-1 has unquestionable biological activity and legitimate prescription use. It is also capable of causing serious adverse effects.

Human studies in people with neuromuscular disease have sometimes shown increased lean mass or growth, but functional benefits have been disappointing.

In an open-label study involving myotonic muscular dystrophy, a recombinant IGF-1 and binding-protein complex increased lean body mass but did not improve muscle strength or function.

In a controlled study involving boys with Duchenne muscular dystrophy, recombinant IGF-1 improved linear growth and increased lean mass, but did not improve the primary walking outcome or overall motor function.

Mecasermin is not approved for ordinary muscle gain. The evidence from rare medical disorders cannot be used to assume that unapproved IGF-1 variants are safe or effective for healthy adults.

Claims for IGF-1 LR3, IGF-1 DES, and mechano growth factor rely heavily on animal studies, laboratory mechanisms, and bodybuilding anecdotes.

Follistatin

Follistatin is scientifically interesting because suppressing the myostatin pathway can produce dramatic muscle growth in animals.

Mouse studies involving follistatin gene delivery reported increased muscle mass and strength.

A small early-stage gene-therapy study evaluated an adeno-associated viral vector expressing follistatin in patients with Becker muscular dystrophy. The treatment was not the same as injecting commercially marketed follistatin-344. The study involved a specialized gene-transfer procedure in patients with a serious genetic disease, not healthy athletes.

The wider history of myostatin-targeted drugs also calls for caution. Clinical programs have often increased muscle volume without delivering proportional improvements in strength or function.

There is no approved follistatin medication for muscle building, and no sound clinical evidence validating online follistatin products for bodybuilding.

How do muscle peptides compare to steroids and SARMs?

Steroids and SARMs act more directly on androgen signaling, while most muscle peptides act indirectly through growth hormone, IGF-1, tissue-repair pathways, or experimental growth regulators.

Anabolic androgenic steroids have a much stronger and more established ability to increase muscle size and strength. They also carry well-documented risks, including suppression of natural testosterone, infertility, adverse cholesterol changes, elevated blood pressure, liver injury with some oral agents, cardiovascular complications, psychiatric effects, and other harms.

SARMs activate the androgen receptor selectively, at least in theory. No SARM is FDA approved for bodybuilding, and the FDA has warned that products marketed as SARMs are associated with serious safety concerns, including liver injury and increased risks of heart attack or stroke.

Growth hormone releasing peptides are not steroid substitutes in any proven sense. They may raise growth hormone or IGF-1, but the muscle and strength effects are less predictable and generally less supported.

Repair peptides such as BPC-157 and TB-500 are even further removed from anabolic steroids. Their marketing is centered on healing and recovery, but reliable human evidence is lacking.

Combining peptides with steroids or SARMs does not solve the evidence problem. It adds more variables, more potential interactions, and more difficulty identifying the cause of an adverse event.

Are muscle growth peptides safe?

The safety of these compounds varies, but unapproved muscle peptides cannot be assumed safe simply because they resemble natural hormones or contain amino acids.

Growth hormone pathway risks

Raising growth hormone and IGF-1 can produce:

• Fluid retention and swelling
• Joint discomfort
• Numbness or tingling
• Headache
• Increased appetite
• Changes in blood glucose and insulin sensitivity
• Possible worsening of sleep apnea
• Changes in blood pressure or heart rate

MK-677 studies have reported increased appetite, edema, muscle pain, higher fasting glucose, and reduced insulin sensitivity in some participants.

The FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. The agency also says available clinical data are limited.

The FDA safety summary for ipamorelin notes peptide-characterization and immunogenicity concerns. It also cites serious adverse events, including deaths, in a study where intravenous ipamorelin was investigated in a medically complex clinical setting. That does not prove that ipamorelin caused every event, but it contradicts claims that the compound has an established clean safety record.

BPC-157 and TB-500 risks

The central safety problem is the lack of adequate human data.

The FDA states that compounded BPC-157 may present immunogenicity risks and peptide-related impurity concerns. It says there is insufficient safety information to determine whether BPC-157 would harm humans through proposed routes of administration.

For the TB-500 fragment, the FDA has cited similar concerns involving aggregation, impurities, and the absence of identified human exposure data.

These risks are separate from manufacturing hazards. An unapproved vial may be contaminated, mislabeled, under-strength, over-strength, or contain a different substance.

IGF-1 risks

Prescription mecasermin carries clinically significant risks. These include hypoglycemia, tonsil or adenoid tissue enlargement, increased pressure around the brain, allergic reactions, and abnormal tissue growth. Because IGF-1 promotes cellular growth and survival signaling, clinicians also approach its use carefully in patients with active or suspected malignancy.

Unapproved variants have even less reliable safety information.

Follistatin risks

Follistatin affects more than muscle. It interacts with activins and reproductive hormone signaling, which raises concerns about unintended effects on fertility, endocrine function, blood vessels, and other tissues.

Gene therapy creates additional risks involving immune reactions, off-target effects, vector exposure, and the difficulty of reversing a long-lasting biological intervention.

A vial marketed as follistatin-344 has not gone through the clinical testing required to define a safe use.

Are these peptides legal and banned in sports?

Most of these substances are not FDA approved for muscle growth, and nearly all are prohibited for athletes governed by the World Anti-Doping Code.

Legal status and anti-doping status are separate questions. A substance may be a legitimate prescription drug but still be prohibited in sport. It may also be unapproved for human use and prohibited under the catch-all rules in the WADA code.

The 2026 WADA Prohibited List is in force and prohibits relevant peptide hormones, growth factors, releasing factors, mimetics, and related modulators at all times, both in competition and out of competition.

Current practical status

• Sermorelin: The original FDA-approved product was discontinued. Current compounded sermorelin products are not FDA-approved products. Sermorelin is prohibited in WADA-tested sport as a growth hormone-releasing factor, and USADA specifically warns athletes about its prohibited status.
• Ipamorelin: Not FDA approved. The FDA has identified significant concerns regarding compounded ipamorelin. It is prohibited in sport as a growth hormone secretagogue.
• CJC-1295: Not FDA approved. It is prohibited in sport as a growth hormone-releasing factor. The FDA has identified limited clinical data and serious reported adverse events.
• MK-677 (ibutamoren): Not FDA approved. It is an investigational non-peptide drug and appears in the FDA Category 2 compounding list because the agency has identified significant safety concerns. It is prohibited in sport as a growth hormone secretagogue.
• BPC-157: Not FDA approved. The FDA has identified insufficient safety information and potential compounding risks. WADA prohibits BPC-157 under the category covering non-approved substances.
• TB-500: Not FDA approved. The FDA reported finding no human clinical studies for the TB-500 fragment during its review. Thymosin beta-4 and its derivatives are prohibited in WADA-tested sport.
• IGF-1: Mecasermin is a prescription-only FDA-approved drug for severe primary IGF-1 deficiency, not muscle enhancement. IGF-1, its analogues, and related growth factors are prohibited in sport.
• IGF-1 LR3, IGF-1 DES, and mechano growth factor: Not FDA approved. They fall within the WADA prohibition on IGF-1 analogues and growth factors.
• Follistatin: No FDA-approved follistatin product exists for muscle building. Follistatin and other myostatin-function modifiers are prohibited in WADA-tested sport.

Compounded drugs are not FDA approved. The FDA does not review compounded products for safety, effectiveness, or manufacturing quality before they are marketed.

What is the honest verdict on muscle growth peptides?

The few compounds with real human data affect hormone markers or lean mass, while most muscle-building claims remain unsupported by reliable evidence. Here is the evidence hierarchy in plain English.

Human biological activity is established

Sermorelin, ipamorelin, and CJC-1295 can stimulate growth hormone signaling in humans. MK-677 can raise growth hormone and IGF-1 and has increased fat-free mass in some clinical populations. Prescription IGF-1 has measurable effects on growth and lean mass in selected patients with rare medical conditions.

Muscle-building benefit is not established

None of those findings proves meaningful hypertrophy, strength improvement, better recovery, or enhanced athletic performance in healthy adults. CJC-1295 and ipamorelin lack robust long-term muscle trials. Sermorelin is not an evidence-based bodybuilding treatment. MK-677 has produced changes in fat-free mass without convincing improvements in strength or function. IGF-1 studies in neuromuscular conditions have often failed to convert increased lean mass into better functional performance.

Evidence is mostly preclinical or highly experimental

BPC-157 remains predominantly an animal-research story. TB-500 lacks established human clinical evidence for muscle or injury recovery. The dramatic reputation of follistatin comes mainly from animal experiments and specialized gene-therapy research. IGF-1 LR3, IGF-1 DES, and mechano growth factor are not validated bodybuilding drugs. The marketing is ahead of the science.

Frequently asked questions

What is the best peptide for muscle growth?

There is no peptide with strong evidence supporting safe and effective muscle growth in healthy adults. MK-677 has increased fat-free mass in some human studies, but it is not a peptide, is not FDA approved, can impair glucose regulation, and has not reliably improved strength.

Do CJC-1295 and ipamorelin build muscle?

They can increase growth hormone signaling, but controlled human trials have not established that the combination builds meaningful muscle or improves strength in healthy people.

Does BPC-157 help muscles recover faster?

Animal studies suggest possible tissue-repair effects, but reliable controlled human trials have not shown that BPC-157 speeds muscle recovery or return to sport.

Is TB-500 the same as thymosin beta-4?

Not exactly. TB-500 generally refers to a synthetic fragment associated with thymosin beta-4. Findings involving the full-length natural protein cannot automatically be attributed to the marketed fragment.

Is IGF-1 safer than steroids?

No simple comparison is valid. IGF-1 and anabolic steroids have different mechanisms and different risks. Prescription IGF-1 can cause serious hypoglycemia and abnormal tissue-growth effects. Unapproved IGF-1 variants have poorly defined safety and quality.

Can tested athletes use muscle peptides with a prescription?

A prescription does not automatically permit use in sport. Athletes subject to anti-doping rules may require an approved Therapeutic Use Exemption, and many performance-oriented uses would not meet the medical criteria for one.

The bottom line

The phrase peptides for muscle growth makes a scattered group of experimental substances sound like an established treatment category. It is not.

Growth hormone releasing compounds can alter hormone levels, but muscle and strength benefits in healthy people remain poorly demonstrated. BPC-157 and TB-500 are promoted as recovery tools despite a serious shortage of controlled human evidence. IGF-1 has legitimate medical uses but carries meaningful risks and is not approved for ordinary muscle gain. Follistatin remains an experimental research strategy, not a proven bodybuilding medication.

Anyone concerned about low muscle mass, slow recovery, declining strength, hormone deficiency, or an injury should speak with a licensed clinician. A proper evaluation can identify treatable medical causes and distinguish a genuine hormone disorder from normal training, nutrition, sleep, or recovery problems.